• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Vaccines / HPV / Gardasil / Silgard / 'We will continue to sell our patented drugs with India-specific pricing'

'We will continue to sell our patented drugs with India-specific pricing'

September 7, 2010 By Jonathan 1 Comment

The Times of India

September 8, 2010

MSD India’s managing director KG Ananthakrishnan spoke to ET’s Khomba Singh on future strategy and shared his views on the Indian government’s proposals on contentious issues such as compulsory licensing, capping FDI in the sector and reviewing of certain sections of Indian patent laws. Excerpts:

Global drugmakers have lobbied hard for review of controversial Section 3(d) of Indian patent laws and patent linkages. MNCs, including Merck, are yet to publicly voice views on the proposal being evaluated by the government?

We have seen the note floated by the PMO and the commerce ministry (ceiling on foreign investment and compulsory licensing). But, before commenting on it, we have to closely study and analyse it in detail. As a philosophy, we value patents because a huge amount of scientific research, time and investment goes into developing new innovator medicines. The Indian government’s policy reforms in intellectual property rights (India adopted new patent regime in 2005) has been in the right direction and regulation has improved. It may not be picture perfect and there may be arguments and debates on certain sections of the laws.

In such debates, the government tends to go for a populist move, keeping the affordability of medicines in mind. Health experts expect prices of drugs to rise if the proposed changes are made.

We follow a responsible pricing strategy, keeping the Indian patients’ affordability in mind, as we have begun with the launch of our diabetes drug Januvia. We will continue to sell our patented drugs with India-specific pricing.

The health ministry has stopped the clinical trails of MSD and GSK’s cervical cancer vaccines by an NGO, after a few vaccinated girls died. Can it affect sales of your vaccines in the country?

There is no problem with the vaccines and they are available in the retail market. Paediatric and gynaecologist bodies in India have also supported the vaccination against cervical cancer. Since Gardasil (Merck’s vaccine brand) is supplied by us, its safety is entirely our responsibility. We have shared whatever information Indian Council of Medical Research and health authorities have asked for. The health minister of Andhra Pradesh (the state where three girls died, post vaccination) has said on record that the deaths were not linked to the vaccvine. Gardasil is a part of the national immunisation programme of 28 countries. About, 74,000 women or 27% of the global deaths due to the disease are in India as per WHO figures. Cervical cancer is the only cancer that has a vaccine and awareness needs to be spread to save lives.

Read Full Article….

Related

Filed Under: Gardasil / Silgard Tagged With: Gardasil/Silgard, HPV, HPV VACCINES, immunizations, Merck, vaccinations, Vaccine Adverse Reactions

Trackbacks

  1. Tweets that mention ‘We will continue to sell our patented drugs with India-specific pricing’ | Sane Vax -- Topsy.com says:
    September 8, 2010 at 12:57 am

    […] This post was mentioned on Twitter by SaneVax, SaneVax. SaneVax said: ‘We will continue to sell our patented drugs with India-specific pricing’ | Sane Vax http://t.co/rMzwCWl […]

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Gardasil: Don’t let your child become “One Less”

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

What’s really in vaccines?

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2025 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in